Coronavirus Knocks Drug Pricing Down – But Not Off – Political Priority List In US
When the top US health official testified before Congress on the budget this past week, drug pricing was barely discussed. What a difference two weeks – and global spread of a novel infectious disease – makes.
You may also be interested in...
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.
HHS Secretary Azar says $1bn of the $2.5bn emergency supplemental funding request is for vaccine development.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.